8 results
DEF 14A
NMRA
Neumora Therapeutics Inc.
25 Apr 24
Definitive proxy
4:05pm
stockholder interests through the exercise of sound judgment using its diversity of experience in these various areas.
The Nominating and Corporate Governance … securities as collateral.
Board Diversity
Among our seven Board members as of April 15, 2024, in accordance with Nasdaq diversity criteria, one
8-K
EX-99.1
NMRA
Neumora Therapeutics Inc.
8 Jan 24
Regulation FD Disclosure
8:32am
structural diversity, target potency and potential target engagement (modelled) 2025 Topline data readout in Alzheimer's disease agitation (2025) 1 NMRA
424B4
NMRA
Neumora Therapeutics Inc.
18 Sep 23
Prospectus supplement with pricing info
4:12pm
-amyloid for AD. This paucity of innovation in therapeutic targets has led to a lack of diversity in treatment options, leading to underserved patient
S-1/A
NMRA
Neumora Therapeutics Inc.
11 Sep 23
IPO registration (amended)
6:07am
. This paucity of innovation in therapeutic targets has led to a lack of diversity in treatment options, leading to underserved patient populations due
S-1
NMRA
Neumora Therapeutics Inc.
25 Aug 23
IPO registration
5:03pm
to a lack of diversity in treatment options, leading to underserved patient populations due to the poor efficacy and side-effect profiles of existing
DRS/A
3oz9e2j4n
9 Aug 23
Draft registration statement (amended)
12:00am
DRS/A
tr3n2j66 p4
30 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
7xjqz
2 May 23
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next